Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA USER FEE CARRY-OVERS COULD FUND 3-6 MONTHS OF OPERATIONS AFTER USER FEE ACT EXPIRES, AGENCY TELLS REP. BARTON; $24 MIL. CARRY-OVER EXPECTED IN FY '97

Executive Summary

FDA would be able to fund up to six months of operations beyond Sept. 30 if the Prescription Drug User Fee Act has not been reauthorized, Deputy Commissioner for External Affairs Sharon Smith Holston indicated in a July 25 letter to House Commerce/Oversight Subcommittee Chairman Barton (R-Tex.).

You may also be interested in...



PDUFA III Or Waxman/Hatch II?: Payors Urge Fix For Generic “Loopholes”

General Motors is among payors urging Congress to address Waxman/Hatch "loophole" legislation as part of the FDA user fee reauthorization bill

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel